WHO ICTRP trial
PegIFNalpha-2a treatment added-on entecavir for HBeAg and HBV DNA negative…
JPRN-UMIN000012454 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-UMIN000012454 |
|---|---|
| Public title | PegIFNalpha-2a treatment added-on entecavir for HBeAg and HBV DNA negative patients treated with long-term entecavir |
| Scientific title | PegIFNalpha-2a treatment added-on entecavir for HBeAg and HBV DNA negative patients treated with long-term entecavir - PegIFNalpha-2a treatment added-on entecavir |
| Primary sponsor | Toranomon Hospital |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Not applicable |
| Countries | Japan |
| Conditions | chronic hepatitis B |
| Interventions | Peg interferon therapy added-on entecavir Entecavir mono therapy |
| Registration date | May 12, 2013 |
| Target size | 100 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: